<?xml version="1.0" encoding="UTF-8"?>

<configuration experimentType="rnaseq_mrna_differential" r_data="1">
    <analytics>
        <assay_groups>
            <assay_group id="g1" label="B-Cells; ALS">
                <assay>SRR1551110</assay>
                <assay>SRR1551063</assay>
                <assay>SRR1551077</assay>
            </assay_group>
            <assay_group id="g2" label="B-Cells; Type 1 Diabetes">
                <assay>SRR1551090</assay>
                <assay>SRR1551010</assay>
                <assay>SRR1551084</assay>
                <assay>SRR1551004</assay>
            </assay_group>
            <assay_group id="g3" label="B-Cells; multiple sclerosis; after IFN-beta treatment">
                <assay>SRR1550999</assay>
                <assay>SRR1551103</assay>
                <assay>SRR1551042</assay>
            </assay_group>
            <assay_group id="g4" label="B-Cells; multiple sclerosis; before IFN-beta treatment">
                <assay>SRR1551035</assay>
                <assay>SRR1550994</assay>
                <assay>SRR1551097</assay>
            </assay_group>
            <assay_group id="g5" label="B-Cells; normal">
                <assay>SRR1551049</assay>
                <assay>SRR1551056</assay>
                <assay>SRR1551070</assay>
                <assay>SRR1550988</assay>
            </assay_group>
            <assay_group id="g6" label="B-Cells; sepsis">
                <assay>SRR1551015</assay>
                <assay>SRR1551022</assay>
                <assay>SRR1551028</assay>
            </assay_group>
            <assay_group id="g7" label="CD4; ALS">
                <assay>SRR1551078</assay>
                <assay>SRR1551064</assay>
                <assay>SRR1551111</assay>
            </assay_group>
            <assay_group id="g8" label="CD4; Type 1 Diabetes">
                <assay>SRR1551085</assay>
                <assay>SRR1551011</assay>
                <assay>SRR1551005</assay>
                <assay>SRR1551091</assay>
            </assay_group>
            <assay_group id="g9" label="CD4; multiple sclerosis; after IFN-beta treatment">
                <assay>SRR1551043</assay>
                <assay>SRR1551104</assay>
                <assay>SRR1551000</assay>
            </assay_group>
            <assay_group id="g10" label="CD4; multiple sclerosis; before IFN-beta treatment">
                <assay>SRR1551036</assay>
                <assay>SRR1551098</assay>
                <assay>SRR1550995</assay>
            </assay_group>
            <assay_group id="g11" label="CD4; normal">
                <assay>SRR1551071</assay>
                <assay>SRR1550989</assay>
                <assay>SRR1551050</assay>
                <assay>SRR1551057</assay>
            </assay_group>
            <assay_group id="g12" label="CD4; sepsis">
                <assay>SRR1551029</assay>
                <assay>SRR1551023</assay>
                <assay>SRR1551016</assay>
            </assay_group>
            <assay_group id="g13" label="CD8; ALS">
                <assay>SRR1551065</assay>
                <assay>SRR1551079</assay>
                <assay>SRR1551112</assay>
            </assay_group>
            <assay_group id="g14" label="CD8; Type 1 Diabetes">
                <assay>SRR1551092</assay>
                <assay>SRR1551006</assay>
                <assay>SRR1551012</assay>
                <assay>SRR1551086</assay>
            </assay_group>
            <assay_group id="g15" label="CD8; multiple sclerosis; after IFN-beta treatment">
                <assay>SRR1551001</assay>
                <assay>SRR1551105</assay>
                <assay>SRR1551044</assay>
            </assay_group>
            <assay_group id="g16" label="CD8; multiple sclerosis; before IFN-beta treatment">
                <assay>SRR1551099</assay>
                <assay>SRR1551037</assay>
                <assay>SRR1550996</assay>
            </assay_group>
            <assay_group id="g17" label="CD8; normal">
                <assay>SRR1551051</assay>
                <assay>SRR1551072</assay>
                <assay>SRR1551058</assay>
                <assay>SRR1550990</assay>
            </assay_group>
            <assay_group id="g18" label="CD8; sepsis">
                <assay>SRR1551024</assay>
                <assay>SRR1551030</assay>
                <assay>SRR1551017</assay>
            </assay_group>
            <assay_group id="g19" label="NK; ALS">
                <assay>SRR1551080</assay>
                <assay>SRR1551113</assay>
                <assay>SRR1551066</assay>
            </assay_group>
            <assay_group id="g20" label="NK; normal">
                <assay>SRR1550991</assay>
                <assay>SRR1551073</assay>
                <assay>SRR1551059</assay>
                <assay>SRR1551052</assay>
            </assay_group>
            <assay_group id="g21" label="monocytes; ALS">
                <assay>SRR1551076</assay>
                <assay>SRR1551109</assay>
                <assay>SRR1551062</assay>
            </assay_group>
            <assay_group id="g22" label="monocytes; Type 1 Diabetes">
                <assay>SRR1551083</assay>
                <assay>SRR1551089</assay>
                <assay>SRR1551009</assay>
                <assay>SRR1551003</assay>
            </assay_group>
            <assay_group id="g23" label="monocytes; multiple sclerosis; after IFN-beta treatment">
                <assay>SRR1551041</assay>
                <assay>SRR1551102</assay>
                <assay>SRR1550998</assay>
            </assay_group>
            <assay_group id="g24" label="monocytes; multiple sclerosis; before IFN-beta treatment">
                <assay>SRR1550993</assay>
                <assay>SRR1551096</assay>
                <assay>SRR1551034</assay>
            </assay_group>
            <assay_group id="g25" label="monocytes; normal">
                <assay>SRR1551055</assay>
                <assay>SRR1551069</assay>
                <assay>SRR1551048</assay>
                <assay>SRR1550987</assay>
            </assay_group>
            <assay_group id="g26" label="monocytes; sepsis">
                <assay>SRR1551027</assay>
                <assay>SRR1551021</assay>
                <assay>SRR1551014</assay>
            </assay_group>
            <assay_group id="g27" label="neutrophils; ALS">
                <assay>SRR1551075</assay>
                <assay>SRR1551108</assay>
                <assay>SRR1551061</assay>
            </assay_group>
            <assay_group id="g28" label="neutrophils; Type 1 Diabetes">
                <assay>SRR1551082</assay>
                <assay>SRR1551088</assay>
                <assay>SRR1551002</assay>
                <assay>SRR1551008</assay>
            </assay_group>
            <assay_group id="g29" label="neutrophils; multiple sclerosis; after IFN-beta treatment">
                <assay>SRR1551040</assay>
                <assay>SRR1550997</assay>
                <assay>SRR1551101</assay>
            </assay_group>
            <assay_group id="g30" label="neutrophils; multiple sclerosis; before IFN-beta treatment">
                <assay>SRR1551095</assay>
                <assay>SRR1551033</assay>
                <assay>SRR1550992</assay>
            </assay_group>
            <assay_group id="g31" label="neutrophils; normal">
                <assay>SRR1551054</assay>
                <assay>SRR1551068</assay>
                <assay>SRR1550986</assay>
                <assay>SRR1551047</assay>
            </assay_group>
            <assay_group id="g32" label="neutrophils; sepsis">
                <assay>SRR1551026</assay>
                <assay>SRR1551020</assay>
                <assay>SRR1551013</assay>
            </assay_group>
            <assay_group id="g33" label="whole blood; ALS">
                <assay>SRR1551114</assay>
                <assay>SRR1551067</assay>
                <assay>SRR1551081</assay>
            </assay_group>
            <assay_group id="g34" label="whole blood; Type 1 Diabetes">
                <assay>SRR1550984</assay>
                <assay>SRR1551087</assay>
                <assay>SRR1551094</assay>
                <assay>SRR1550985</assay>
            </assay_group>
            <assay_group id="g35" label="whole blood; multiple sclerosis; after IFN-beta treatment">
                <assay>SRR1551107</assay>
                <assay>SRR1550983</assay>
                <assay>SRR1551046</assay>
            </assay_group>
            <assay_group id="g36" label="whole blood; multiple sclerosis; before IFN-beta treatment">
                <assay>SRR1551039</assay>
                <assay>SRR1551100</assay>
                <assay>SRR1550982</assay>
            </assay_group>
            <assay_group id="g37" label="whole blood; normal">
                <assay>SRR1551074</assay>
                <assay>SRR1551060</assay>
                <assay>SRR1551053</assay>
                <assay>SRR1550981</assay>
            </assay_group>
            <assay_group id="g38" label="whole blood; sepsis">
                <assay>SRR1551032</assay>
                <assay>SRR1551025</assay>
                <assay>SRR1551019</assay>
            </assay_group>
        </assay_groups>
        <contrasts>
            <contrast id="g5_g1" cttv_primary="1">
                <name>'ALS' vs 'normal' in 'B-Cells'</name>
                <reference_assay_group>g5</reference_assay_group>
                <test_assay_group>g1</test_assay_group>
            </contrast>
            <contrast id="g5_g2" cttv_primary="1">
                <name>'Type 1 Diabetes' vs 'normal' in 'B-Cells'</name>
                <reference_assay_group>g5</reference_assay_group>
                <test_assay_group>g2</test_assay_group>
            </contrast>
            <contrast id="g5_g4" cttv_primary="0">
                <name>'multiple sclerosis; before IFN-beta treatment' vs 'normal' in 'B-Cells'</name>
                <reference_assay_group>g5</reference_assay_group>
                <test_assay_group>g4</test_assay_group>
            </contrast>
            <contrast id="g5_g3" cttv_primary="0">
                <name>'multiple sclerosis; after IFN-beta treatment' vs 'normal' in 'B-Cells'</name>
                <reference_assay_group>g5</reference_assay_group>
                <test_assay_group>g3</test_assay_group>
            </contrast>
            <contrast id="g5_g6" cttv_primary="1">
                <name>'sepsis' vs 'normal' in 'B-Cells'</name>
                <reference_assay_group>g5</reference_assay_group>
                <test_assay_group>g6</test_assay_group>
            </contrast>
            <contrast id="g11_g7" cttv_primary="1">
                <name>'ALS' vs 'normal' in 'CD4'</name>
                <reference_assay_group>g11</reference_assay_group>
                <test_assay_group>g7</test_assay_group>
            </contrast>
            <contrast id="g11_g8" cttv_primary="1">
                <name>'Type 1 Diabetes' vs 'normal' in 'CD4'</name>
                <reference_assay_group>g11</reference_assay_group>
                <test_assay_group>g8</test_assay_group>
            </contrast>
            <contrast id="g11_g10" cttv_primary="0">
                <name>'multiple sclerosis; before IFN-beta treatment' vs 'normal' in 'CD4'</name>
                <reference_assay_group>g11</reference_assay_group>
                <test_assay_group>g10</test_assay_group>
            </contrast>
            <contrast id="g11_g9" cttv_primary="0">
                <name>'multiple sclerosis; after IFN-beta treatment' vs 'normal' in 'CD4'</name>
                <reference_assay_group>g11</reference_assay_group>
                <test_assay_group>g9</test_assay_group>
            </contrast>
            <contrast id="g11_g12" cttv_primary="1">
                <name>'sepsis' vs 'normal' in 'CD4'</name>
                <reference_assay_group>g11</reference_assay_group>
                <test_assay_group>g12</test_assay_group>
            </contrast>
            <contrast id="g17_g13" cttv_primary="1">
                <name>'ALS' vs 'normal' in 'CD8'</name>
                <reference_assay_group>g17</reference_assay_group>
                <test_assay_group>g13</test_assay_group>
            </contrast>
            <contrast id="g17_g14" cttv_primary="1">
                <name>'Type 1 Diabetes' vs 'normal' in 'CD8'</name>
                <reference_assay_group>g17</reference_assay_group>
                <test_assay_group>g14</test_assay_group>
            </contrast>
            <contrast id="g17_g16" cttv_primary="0">
                <name>'multiple sclerosis; before IFN-beta treatment' vs 'normal' in 'CD8'</name>
                <reference_assay_group>g17</reference_assay_group>
                <test_assay_group>g16</test_assay_group>
            </contrast>
            <contrast id="g17_g15" cttv_primary="0">
                <name>'multiple sclerosis; after IFN-beta treatment' vs 'normal' in 'CD8'</name>
                <reference_assay_group>g17</reference_assay_group>
                <test_assay_group>g15</test_assay_group>
            </contrast>
            <contrast id="g17_g18" cttv_primary="1">
                <name>'sepsis' vs 'normal' in 'CD8'</name>
                <reference_assay_group>g17</reference_assay_group>
                <test_assay_group>g18</test_assay_group>
            </contrast>
            <contrast id="g20_g19" cttv_primary="1">
                <name>'ALS' vs 'normal' in 'NK'</name>
                <reference_assay_group>g20</reference_assay_group>
                <test_assay_group>g19</test_assay_group>
            </contrast>
            <contrast id="g25_g21" cttv_primary="1">
                <name>'ALS' vs 'normal' in 'monocytes'</name>
                <reference_assay_group>g25</reference_assay_group>
                <test_assay_group>g21</test_assay_group>
            </contrast>
            <contrast id="g25_g22" cttv_primary="1">
                <name>'Type 1 Diabetes' vs 'normal' in 'monocytes'</name>
                <reference_assay_group>g25</reference_assay_group>
                <test_assay_group>g22</test_assay_group>
            </contrast>
            <contrast id="g25_g24" cttv_primary="0">
                <name>'multiple sclerosis; before IFN-beta treatment' vs 'normal' in 'monocytes'</name>
                <reference_assay_group>g25</reference_assay_group>
                <test_assay_group>g24</test_assay_group>
            </contrast>
            <contrast id="g25_g23" cttv_primary="0">
                <name>'multiple sclerosis; after IFN-beta treatment' vs 'normal' in 'monocytes'</name>
                <reference_assay_group>g25</reference_assay_group>
                <test_assay_group>g23</test_assay_group>
            </contrast>
            <contrast id="g25_g26" cttv_primary="1">
                <name>'sepsis' vs 'normal' in 'monocytes'</name>
                <reference_assay_group>g25</reference_assay_group>
                <test_assay_group>g26</test_assay_group>
            </contrast>
            <contrast id="g31_g27" cttv_primary="1">
                <name>'ALS' vs 'normal' in 'neutrophils'</name>
                <reference_assay_group>g31</reference_assay_group>
                <test_assay_group>g27</test_assay_group>
            </contrast>
            <contrast id="g31_g28" cttv_primary="1">
                <name>'Type 1 Diabetes' vs 'normal' in 'neutrophils'</name>
                <reference_assay_group>g31</reference_assay_group>
                <test_assay_group>g28</test_assay_group>
            </contrast>
            <contrast id="g31_g30" cttv_primary="0">
                <name>'multiple sclerosis; before IFN-beta treatment' vs 'normal' in 'neutrophils'</name>
                <reference_assay_group>g31</reference_assay_group>
                <test_assay_group>g30</test_assay_group>
            </contrast>
            <contrast id="g31_g29" cttv_primary="0">
                <name>'multiple sclerosis; after IFN-beta treatment' vs 'normal' in 'neutrophils'</name>
                <reference_assay_group>g31</reference_assay_group>
                <test_assay_group>g29</test_assay_group>
            </contrast>
            <contrast id="g31_g32" cttv_primary="1">
                <name>'sepsis' vs 'normal' in 'neutrophils'</name>
                <reference_assay_group>g31</reference_assay_group>
                <test_assay_group>g32</test_assay_group>
            </contrast>
            <contrast id="g37_g33" cttv_primary="1">
                <name>'ALS' vs 'normal' in 'whole blood'</name>
                <reference_assay_group>g37</reference_assay_group>
                <test_assay_group>g33</test_assay_group>
            </contrast>
            <contrast id="g37_g34" cttv_primary="1">
                <name>'Type 1 Diabetes' vs 'normal' in 'whole blood'</name>
                <reference_assay_group>g37</reference_assay_group>
                <test_assay_group>g34</test_assay_group>
            </contrast>
            <contrast id="g37_g36" cttv_primary="0">
                <name>'multiple sclerosis; before IFN-beta treatment' vs 'normal' in 'whole blood'</name>
                <reference_assay_group>g37</reference_assay_group>
                <test_assay_group>g36</test_assay_group>
            </contrast>
            <contrast id="g37_g35" cttv_primary="0">
                <name>'multiple sclerosis; after IFN-beta treatment' vs 'normal' in 'whole blood'</name>
                <reference_assay_group>g37</reference_assay_group>
                <test_assay_group>g35</test_assay_group>
            </contrast>
            <contrast id="g37_g38" cttv_primary="1">
                <name>'sepsis' vs 'normal' in 'whole blood'</name>
                <reference_assay_group>g37</reference_assay_group>
                <test_assay_group>g38</test_assay_group>
            </contrast>
        </contrasts>
    </analytics>
</configuration>
